Skip directly to content

Treatment checklist

What should you take into account before starting INFLECTRA®(infliximab)?

Fully review the INFLECTRA® (infliximab) Full Prescribing Information, including Important Safety Information, prior to starting treatment.

Additionally, take the following considerations into particular account:

  • Actively monitor patients for infections:4
    • Screenings for latent/active tuberculosis and hepatitis B
  • Vaccinate:4
    • Bring paediatric patients up to date with all vaccinations prior to initiating treatment if possible
  • Discuss potential health issues with patients:4
    • Heart problems
    • Lymphoma or any other cancer
    • Lung disease or heavy smoking
    • Problems that affect the nervous system, such as multiple sclerosis, Guillain-Barre syndrome, or optic neuritis
    • Abnormal skin openings
    • Imminent operations
    • Dental issues, including planned operations or procedures
  • Monitor:4
    • The general condition of patients (e.g., symptoms of bacterial or viral infections, fever, ulcers or purulent discharge from fistulas)

INFLECTRA® (infliximab) MUST NOT be given in:4

  • Cases of tuberculosis, or other severe infections such as sepsis, abscesses and opportunistic infections
  • Patients with a history of hypersensitivity to infliximab (or any of its excipients) or other murine proteins

 

What should you consider or monitor during INFLECTRA® (infliximab) treatment?

  • Consider the long half-life of infliximab when planning certain vaccinations or surgical procedures:4
    • Closely monitor patients who require surgery for infections
  • Avoid concurrent administration of INFLECTRA® (infliximab) with live vaccines or therapeutic infectious agents such as live attenuated bacteria:4
    • Also avoid administration of live vaccines in infants ≤6 months of age who have been exposed to infliximab in utero

Download a copy of the checklist here

 

Review special warnings and precautions for use (Section 4.4 of the SmPC)

INFLECTRA (infliximab) produkto charakteristikų santrauka

 

 

*CT-P13 was designed with comparable efficacy, safety and quality to reference infliximab, to increase the treatment options for your Crohn’s disease and ulcerative colitis patients.5,6 Increasing real-world experience confirms the CT-P13 clinical efficacy and safety profile.7

 

ECCO, European Crohn’s and Colitis Organisation; IBD, Inflammatory bowel disease.

Šaltiniai: 

1. Gecse KB, et al. J Crohns Colitis 2016;10(2):133-40. 2. Jørgensen KK, et al. Lancet 2017;389:2304-16. 3. QuintilesIMS. MIDAS, February 2017. 4. INFLECTRA® Summary of Product Characteristics. 5. European Public Assessment Report: INFLECTRA™. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_asses.... Accessed December 2017. 6. European Medicines Agency. Guidelines on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ 2012/06/WC500128686.pdf. Accessed December 2017. 7. Danese S, et al. J Crohns Colitis 2017;11:26-34.

PP-IFA-LTU-0002